Advertisement

Comparing the influence of exercise intensity on brain-derived neurotrophic factor serum levels in people with Parkinson’s disease: a pilot study

  • Ailish O’Callaghan
  • Marguerite Harvey
  • David Houghton
  • William K. GrayEmail author
  • Kathryn L. Weston
  • Lloyd L. Oates
  • Barbara Romano
  • Richard W. Walker
Original Article

Abstract

Introduction

Endogenous brain-derived neurotrophic factor (BDNF) is thought to be protective against the neurodegeneration seen in Parkinson’s disease (PD), and is thought to increase during exercise. This has been proposed as a possible mechanism by which exercise improves outcomes for people with PD. We conducted a pilot study to investigate the role of exercise intensity on BDNF levels in people with PD.

Methods

Participants of early- to mid-stage disease were recruited from a single PD service in north-east England, UK into two separate studies of exercise in PD, one involving moderate-intensity continuous training (MICT) and one involving high-intensity interval training (HIIT), both had control groups. In both the interventions, participants exercise three times per week for 12 weeks. Blood samples were taken for BDNF analysis at the start and end of the first session and the start and end of the final session, with corresponding samples taken in controls.

Results

Data were available for 27 participants (13 intervention, 14 control) in the MICT intervention and 17 (9 intervention, 8 control) in the HIIT intervention. BDNF level did not rise significantly from the start to end of individual sessions. Across the 12 week period, they rose significantly in the HIIT intervention group, but not in controls or the MICT intervention group.

Conclusions

High-intensity interval training appears to have a greater impact on BDNF than MICT. Future work should directly compare exercise modalities and investigate the impact of BDNF levels on disease progression and quality of life.

Keywords

Parkinson’s disease High-intensity interval training Physiotherapy High-intensity exercise Brain-derived neurotrophic factor 

Notes

Acknowledgements

We thank all people with PD who participated in this study. We would also like to thank all members of the Parkinson’s Team and the Research and Development Department at Northumbria Healthcare NHS Foundation Trust who assisted in data collection, in particular Steve Dodds and Moire McDonald.

Author contribution

This study was conceived, organised and managed by AOC, MH, RW, WKG, KW and LO. Data collection was done by AOC, MH, WKG and RW. Statistical analysis and writing of the first draft of the paper was done by BR, MH and WKG. All the listed authors were involved in the preparation, review and critique of the final manuscript. All the authors have approved the final article for submission.

Funding

The MICT study was funded by a Parkinson’s UK innovation grant and a British Geriatrics Society SpR start-up grant. This HIIT study was funded by a grant from The Graham Wylie Foundation, UK. Speedflex Europe Ltd allowed use of their facilities and equipment free of charge. Neither the Graham Wylie Foundation, Speedflex Europe Ltd nor any employee of Speedflex Europe Ltd had any role in the design of the study, in data collection or analysis, in the writing of this manuscript, or in the decision to submit this manuscript for publication. Northumbria Healthcare NHS Foundation Trust acknowledges the support of the National Institute of Health Research Clinical Research Network (NIHR CRN).

Compliance with ethical standards

Conflict of interest

Dr Kathryn Weston was employed by Speedflex Europe Ltd as an exercise physiologist from July 2013 to January 2014 but was not involved with the company at the time of the study. All the other authors report no conflicts of interest.

Research involving human participants

All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and the national ethical review boards cited below. The MICT intervention protocol was approved by Newcastle and North Tyneside Research Ethics Committee (reference number: 12/NE/0188). The study protocol was registered on the ISRCTN database (ISRCTN13611537). The HIIT intervention protocol was approved by Newcastle and North Tyneside Research Ethics Committee (reference number: 15/NE/0257). The study protocol was registered on the ISRCTN database (ISRCTN75458559). Northumbria Healthcare NHS Foundation Trust was responsible for study integrity and conduct. The studies were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study. Consent was obtained by a senior member of the research team prior to enrolment. All participants had capacity to consent.

References

  1. 1.
    Sampaio TB, Savall AS, Gutierrez MEZ et al (2017) Neurotrophic factors in Alzheimer’s and Parkinson’s diseases: implications for pathogenesis and therapy. Neural Regen Res 12:549–557CrossRefGoogle Scholar
  2. 2.
    Erickson KI, Prakash RS, Voss MW et al (2010) Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci 30:5368–5375CrossRefGoogle Scholar
  3. 3.
    Lommatzsch M, Zingler D, Schuhbaeck K et al (2005) The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26:115–123CrossRefGoogle Scholar
  4. 4.
    Parain K, Murer MG, Yan Q et al (1999) Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. NeuroReport 10:557–561CrossRefGoogle Scholar
  5. 5.
    Howells DW, Porritt MJ, Wong JY et al (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166:127–135CrossRefGoogle Scholar
  6. 6.
    Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63:71–124CrossRefGoogle Scholar
  7. 7.
    Hyman C, Hofer M, Barde YA et al (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232CrossRefGoogle Scholar
  8. 8.
    Lu B, Nagappan G, Guan X et al (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14:401–416CrossRefGoogle Scholar
  9. 9.
    Jimenez-Maldonado A, Renteria I, Garcia-Suarez PC et al (2018) The impact of high-intensity interval training on brain derived neurotrophic factor in brain: a mini-review. Front Neurosci 12:839CrossRefGoogle Scholar
  10. 10.
    Schmolesky MT, Webb DL, Hansen RA (2013) The effects of aerobic exercise intensity and duration on levels of brain-derived neurotrophic factor in healthy men. J Sports Sci Med 12:502–511PubMedPubMedCentralGoogle Scholar
  11. 11.
    da Silva PG, Domingues DD, de Carvalho LA et al (2016) Neurotrophic factors in Parkinson’s disease are regulated by exercise: evidence-based practice. J Neurol Sci 363:5–15CrossRefGoogle Scholar
  12. 12.
    Fumagalli F, Racagni G, Riva MA (2006) Shedding light into the role of BDNF in the pharmacotherapy of Parkinson’s disease. Pharmacogenom J 6:95–104CrossRefGoogle Scholar
  13. 13.
    Ahlskog JE (2011) Pathological behaviors provoked by dopamine agonist therapy of Parkinson’s disease. Physiol Behav 104:168–172CrossRefGoogle Scholar
  14. 14.
    Goodwin VA, Richards SH, Taylor RS et al (2008) The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 23:631–640CrossRefGoogle Scholar
  15. 15.
    Gibala MJ, Little JP, Macdonald MJ et al (2012) Physiological adaptations to low-volume, high-intensity interval training in health and disease. J Physiol 590:1077–1084CrossRefGoogle Scholar
  16. 16.
    Schenkman M, Moore CG, Kohrt WM et al (2018) Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol 75:219–226CrossRefGoogle Scholar
  17. 17.
    Wisloff U, Stoylen A, Loennechen JP et al (2007) Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 115:3086–3094CrossRefGoogle Scholar
  18. 18.
    Harvey M, Weston KL, Gray WK et al (2019) High-intensity interval training in people with Parkinson’s disease: a randomized, controlled feasibility trial. Clin Rehabil 33:428–438CrossRefGoogle Scholar
  19. 19.
    Hurst C, Weston KL, Weston M (2019) The effect of 12 weeks of combined upper- and lower-body high-intensity interval training on muscular and cardiorespiratory fitness in older adults. Aging Clin Exp Res 31:661–671CrossRefGoogle Scholar
  20. 20.
    Ellis T, Boudreau JK, DeAngelis TR et al (2013) Barriers to exercise in people with Parkinson disease. Phys Ther 93:628–636CrossRefGoogle Scholar
  21. 21.
    Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRefGoogle Scholar
  22. 22.
    Coelho FG, Gobbi S, Andreatto CA et al (2013) Physical exercise modulates peripheral levels of brain-derived neurotrophic factor (BDNF): a systematic review of experimental studies in the elderly. Arch Gerontol Geriatr 56:10–15CrossRefGoogle Scholar
  23. 23.
    Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77:288–294CrossRefGoogle Scholar
  24. 24.
    Coetsee C, Terblanche E (2017) Cerebral oxygenation during cortical activation: the differential influence of three exercise training modalities. A randomized controlled trial. Eur J Appl Physiol 117:1617–1627CrossRefGoogle Scholar
  25. 25.
    Robinson MM, Lowe VJ, Nair KS (2018) Increased brain glucose uptake after 12 weeks of aerobic high-intensity interval training in young and older adults. J Clin Endocrinol Metab 103:221–227CrossRefGoogle Scholar
  26. 26.
    Saucedo Marquez CM, Vanaudenaerde B, Troosters T et al (2015) High-intensity interval training evokes larger serum BDNF levels compared with intense continuous exercise. J Appl Physiol 119:1363–1373CrossRefGoogle Scholar
  27. 27.
    Cabral-Santos C, Castrillon CI, Miranda RA et al (2016) Inflammatory cytokines and BDNF response to high-intensity intermittent exercise: effect the exercise volume. Front Physiol 7:509CrossRefGoogle Scholar
  28. 28.
    Enette L, Vogel T, Fanon JL et al (2017) Effect of interval and continuous aerobic training on basal serum and plasma brain-derived neurotrophic factor values in seniors: a systematic review of intervention studies. Rejuvenation Res 20:473–483CrossRefGoogle Scholar
  29. 29.
    Polacchini A, Metelli G, Francavilla R et al (2015) A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci Rep 5:17989CrossRefGoogle Scholar
  30. 30.
    Molendijk ML, Haffmans JP, Bus BA et al (2012) Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 7:e48046CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Northumbria Healthcare NHS Foundation Trust, North Tyneside General HospitalNorth ShieldsUK
  2. 2.North Cumbria University Hospitals NHS TrustCumberland InfirmaryCarlisleUK
  3. 3.Institute of Neuroscience, Newcastle UniversityNewcastle upon TyneUK
  4. 4.School of Health and Social CareTeesside UniversityMiddlesbroughUK
  5. 5.Medical SchoolUniversity of BresciaBresciaItaly
  6. 6.Institute of Health and Society, Newcastle UniversityNewcastle-upon-TyneUK

Personalised recommendations